Artemisinin-Based Antimalarial Combinations and Clinical Response in Cameroon
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy of artesunate-amodiaquine, dihydroartemisinin-piperaquine, in
comparison with artemether-lumefantrine during 42 days follow up period in 720 children with
acute uncomplicated P. falciparum malaria, in two different endemic ecological areas -
Savanna and equatorial forest regions of Cameroon.
We have set as specific objectives:
- To assess the efficacy of artesunate-amodiaquine, dihydroartemisinin-piperaquine, in
comparison with artemether-lumefantrine during 14 and 28 days follow up period in
children with acute uncomplicated P. falciparum malaria in two different endemic areas.
- To evaluate the safety of artesunate-amodiaquine, dihydroartemisinin-piperaquine, in
comparison with artemether-lumefantrine during 42 days follow up period in children with
acute uncomplicated P. falciparum malaria.
- To determine parasite clearance time (PCT) and fever clearance time (FCT) following the
administration of the three trial regimens.
- To investigate the treatment response based on WHO criteria (WHO, 2003) in patients in
all groups after trial.
- To investigate the Single Nucleotide Polymorphisms (SNPs) and microsatellite markers of
genes associated with drug resistance
Phase:
Phase 3
Details
Lead Sponsor:
University of Yaounde 1
Collaborators:
Gates Malaria Partnership World Health Organization